The benefits and harms of Chinese medicinal herbs for the treatment of rapidly progressive glomerulonephritis in adult patients

Abstract

Objective: The aim of this review was to assess the benefits and harms of Chinese medicinal herbs for the treatment of rapidly progressive glomerulonephritis (RPGN) in adult patients. Methods: Our study included only randomized controlled trials (RCTs). We designed a strategy for searching the EMBASE, CENTRAL, PubMed, CBM, CNKI, and VIP. All studies were analyzed using the criteria of the Cochrane Handbook. All studies included were assessed the risk of bias. Review Manager ver. 5.3.5 was used for the data analysis. GRADE profiler was used to evaluate quality. Results: Two studies were studied (74 Chinese participants were included). We found that compared with supportive therapies combined with specific therapies, Chinese medicinal formulae plus supportive therapies combined with specific therapies significantly reduced the serum creatinine levels (SCr; two studies, 62 participants: mean difference (MD),-145.93 μmol/L; 95% confidence interval (CI),-236.75 to-55.11; I 2 =0%) and utilization number of methylprednisolone and prednisone (two studies, 74 participants: MD,-1.64 g; 95% CI,-1.87 to-1.40; I 2 =0%). Conclusion: Our study suggested that there were insufficient evidences to confirm that the use of Chinese medicinal formulae for adults with RPGN was beneficial and safe.

Protective activity of sappanchalcone against oxygen glucose deprivation/re-oxygenation-induced renal tubular epithelial cell injury via TNFRSF1A/NF-kB pathway

“…Several traditional Chinese medicines have been shown to have immunosuppressive property and antioxidant activity. It is of great significance to develop the active components of traditional Chinese medicines for the treatment of kidney disease (Liu et al, 2021). Meanwhile, Sap played an anti-inflammatory role in a variety of human sicknesses, like rheumatoid arthritis (Jung et al, 2015).…”

Mechanism of Baicalein in the treatment of arthritis by regulating JNK/ERK/p38MAPK and PI3K/Akt signaling pathways

“…TAK binding protein (TAB) activates TAK and mediates signal transduction of transforming growth factor. TAK also activates MKK4, which in turn activates P38 (Liu et al, 2020). Nuclear translocation occurs after P38 activation, causing phosphorylation and activation of many protein kinases and transcription factors (Jeong et al, 2016;Zhou et al, 2016;Wang et al, 2015).…”